Open-label pitolisant

Phase 3Small molecule

Open-label pitolisant is one of 17 small molecule programs targeting Idiopathic Hypersomnia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Idiopathic HypersomniaActive, not recruiting

Idiopathic HypersomniaPhase 3

Active, not recruiting

Competition

Competitive Landscape

23 competitors in Idiopathic Hypersomnia

#DrugCompanyPhaseTrials

Biaxin

AbbVie

Approved

—2

Romazicon

CConrado Roberto Hoffmann Filho

Approved

—3

Wakix

HHarmony Biosciences Management, Inc.

Phase 3

1 4

JZP258

Jazz Pharmaceuticals

Approved

1 5

ALKS 37

AAlkermes, Inc.

Phase 3

2 6

Xyrem

Low Sodium Oxybate

2 8

Sunosi

AAxsome Therapeutics, Inc.

Phase 2

1 9

Provigil

NNuvo Research GmbH

Phase 2

1 10

JZP-258

Jazz Pharmaceuticals

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Idiopathic Hypersomnia1 trial

A Phase 3 Study to Assess the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia

Completed·HHarmony Biosciences Management, Inc.·Phase 3·NCT05156047·214 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Open-label pitolisant. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Open-label pitolisant compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Open-label pitolisant. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Harmony Biosciences Management, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: HHarmony Biosciences Management, Inc.

Open-label pitolisant

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Idiopathic Hypersomnia1 trial

References

Drug Info

Quick Facts

Related News